A previous study from our laboratory had demonstrated that in-vivo administration of H19 siRNA induced hyperglycemia, hyperinsulinemia, hyperlipidemia and impaired oral glucose, insulin and pyruvate tolerance in mice (Goyal et al. 2019). The gene discussed is INS; the disease is Hyperinsulinemia.